Walter Ling

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Clinical treatment of opioid addiction and dependence
    Walter Ling
    Integrated Substance Abuse Programs, University of California Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 84:285-95. 2003
  2. ncbi request reprint Buprenorphine: blending practice and research
    Walter Ling
    Integrated Substance Abuse Programs, University of California, Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    J Subst Abuse Treat 23:87-92. 2002
  3. ncbi request reprint Why we do what we do-delivery of buprenorphine and the treatment of opioid addiction
    Walter Ling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Addiction 102:1908-9. 2007
  4. ncbi request reprint Clinical efficacy of buprenorphine: comparisons to methadone and placebo
    Walter Ling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, School of Medicine, University of California Los Angles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles 90025, CA, USA
    Drug Alcohol Depend 70:S49-57. 2003
  5. doi request reprint Buprenorphine for opioid dependence
    Walter Ling
    Integrated Substance Abuse Programs ISAP, University of California at Los Angeles, CA, USA
    Expert Rev Neurother 9:609-16. 2009
  6. doi request reprint Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial
    Walter Ling
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    JAMA 304:1576-83. 2010
  7. ncbi request reprint Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers
    Edythe D London
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90024 1759, USA
    Biol Psychiatry 58:770-8. 2005
  8. pmc Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
    Keith G Heinzerling
    Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Drug Alcohol Depend 109:20-9. 2010
  9. pmc Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology
    Larissa J Mooney
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    Contemp Clin Trials 34:196-204. 2013
  10. pmc From research to the real world: buprenorphine in the decade of the Clinical Trials Network
    Walter Ling
    Pacific Region Node, University of California, Los Angeles, USA
    J Subst Abuse Treat 38:S53-60. 2010

Detail Information

Publications82

  1. ncbi request reprint Clinical treatment of opioid addiction and dependence
    Walter Ling
    Integrated Substance Abuse Programs, University of California Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 84:285-95. 2003
  2. ncbi request reprint Buprenorphine: blending practice and research
    Walter Ling
    Integrated Substance Abuse Programs, University of California, Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    J Subst Abuse Treat 23:87-92. 2002
    ..However, successful implementation will require changes in the understanding and attitude of clinicians, policymakers, and society...
  3. ncbi request reprint Why we do what we do-delivery of buprenorphine and the treatment of opioid addiction
    Walter Ling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Addiction 102:1908-9. 2007
  4. ncbi request reprint Clinical efficacy of buprenorphine: comparisons to methadone and placebo
    Walter Ling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, School of Medicine, University of California Los Angles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles 90025, CA, USA
    Drug Alcohol Depend 70:S49-57. 2003
    ..Also reviewed are three placebo-controlled trials and a buprenorphine/methadone detoxification study. Overall, this series of studies did firmly establish the efficacy of buprenorphine alone and in comparison to methadone...
  5. doi request reprint Buprenorphine for opioid dependence
    Walter Ling
    Integrated Substance Abuse Programs ISAP, University of California at Los Angeles, CA, USA
    Expert Rev Neurother 9:609-16. 2009
    ....
  6. doi request reprint Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial
    Walter Ling
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    JAMA 304:1576-83. 2010
    ..Limitations of existing pharmacological treatments for opioid dependence include low adherence, medication diversion, and emergence of withdrawal symptoms...
  7. ncbi request reprint Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers
    Edythe D London
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90024 1759, USA
    Biol Psychiatry 58:770-8. 2005
    ..The links between cognitive impairment and these cerebral abnormalities are not established...
  8. pmc Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
    Keith G Heinzerling
    Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Drug Alcohol Depend 109:20-9. 2010
    ..To compare modafinil to placebo for reducing methamphetamine (MA) use, improving retention, and reducing depressive symptoms and MA cravings. Rates of adverse events and cigarette smoking with modafinil versus placebo were also compared...
  9. pmc Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology
    Larissa J Mooney
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    Contemp Clin Trials 34:196-204. 2013
    ..This paper describes the design and rationale for this study...
  10. pmc From research to the real world: buprenorphine in the decade of the Clinical Trials Network
    Walter Ling
    Pacific Region Node, University of California, Los Angeles, USA
    J Subst Abuse Treat 38:S53-60. 2010
    ..Furthermore, this article explores current issues and future challenges that may require additional CTN efforts...
  11. ncbi request reprint Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
    Keith G Heinzerling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
    Drug Alcohol Depend 85:177-84. 2006
    ..To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence...
  12. pmc Gabapentin improves cold-pressor pain responses in methadone-maintained patients
    Peggy Compton
    School of Nursing, University of California, Los Angeles, CA 90095, United States
    Drug Alcohol Depend 109:213-9. 2010
    ..These results support that GPN, as prescribed for the treatment of neuropathic pain, is effective in decreasing OIH in patients who are abstinent and stable in methadone treatment...
  13. doi request reprint Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence
    Walter Ling
    University of California, Los Angeles, 90025, USA
    Addiction 107:361-9. 2012
    ..To evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence...
  14. pmc Comparison of buprenorphine treatment for opioid dependence in 3 settings
    Karen Miotto
    Department of Psychiatry, University of California at Los Angeles, CA, USA
    J Addict Med 6:68-76. 2012
    ..Although use of buprenorphine in the treatment of opioid dependence is expected to continue to increase, little is known about the optimal setting for providing the medical and psychosocial care required with buprenorphine pharmacotherapy...
  15. pmc A comparison of buprenorphine taper outcomes between prescription opioid and heroin users
    Suzanne Nielsen
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA
    J Addict Med 7:33-8. 2013
    ....
  16. ncbi request reprint Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence
    Steven Shoptaw
    Center for Health Promotion and Disease Prevention, Department of Family Medicine, David Geffen School of Medicine at UCLA, 10880 Wilshire Blvd, Suite 1800, Los Angeles, CA 90024, USA
    Drug Alcohol Depend 85:12-8. 2006
    ..This project evaluated the efficacy of sertraline (50mg bid) and contingency management (CM) for the treatment of methamphetamine dependence...
  17. pmc Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes
    Maureen Hillhouse
    University of California, Los Angeles, Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    J Addict Dis 29:23-9. 2010
    ..004). Results also indicate that participants attended fewer days of treatment if they received anxiety, nausea, or diarrhea medication compared to no medication (all P values < .05)...
  18. pmc Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
    Steven Shoptaw
    Department of Family Medicine, David Geffen School of Medicine at UCLA, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095, USA
    Drug Alcohol Depend 96:222-32. 2008
    ..A secondary objective compared bupropion to placebo for reducing cigarette smoking among MA dependent participants...
  19. doi request reprint Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence
    Steve Shoptaw
    S David Geffen School of Medicine at UCLA, Department of Family Medicine, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095, USA
    J Addict Dis 27:13-23. 2008
    ..The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy...
  20. ncbi request reprint Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers
    Bradley Voytek
    Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90024, USA
    Synapse 57:113-5. 2005
  21. pmc Participant characteristics and buprenorphine dose
    Maureen Hillhouse
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    Am J Drug Alcohol Abuse 37:453-9. 2011
    ..Clinical parameters for determining buprenorphine dose have not been adequately examined in treatment outcome research...
  22. ncbi request reprint Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    Clin Neurophysiol 115:194-8. 2004
    ..Exposure to methamphetamine is associated with long-lasting reductions in markers for dopaminergic neurons in preclinical models and in humans. These changes may be associated with alterations in brain electrical activity and in cognition...
  23. pmc A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
    Walter Ling
    David Geffen School of Medicine, NPI Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA
    Addiction 100:1090-100. 2005
    ....
  24. ncbi request reprint A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals
    Richard A Rawson
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    Addiction 101:267-74. 2006
    ..The present study sought to directly compare the effectiveness of (CM) and (CBT) alone and in combination in reducing stimulant use...
  25. ncbi request reprint Management of methamphetamine abuse and dependence
    Walter Ling
    Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, University of California Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    Curr Psychiatry Rep 8:345-54. 2006
    ..Clinicians and researchers must interact to efficiently address the problems of methamphetamine dependence, a major drug problem in the United States and the world...
  26. pmc Buprenorphine tapering schedule and illicit opioid use
    Walter Ling
    University of California, Los Angeles, CA 90025, USA
    Addiction 104:256-65. 2009
    ..To compare the effects of a short or long taper schedule after buprenorphine stabilization on participant outcomes as measured by opioid-free urine tests at the end of each taper period...
  27. doi request reprint Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone
    Walter Ling
    Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA
    J Addict Med 6:118-23. 2012
    ..This study investigated the use of buprenorphine (0.3 mg) plus ultra-low-dose naloxone (0.02 mg) (BUP + ULDN) as compared with buprenorphine alone (0.3 mg) (BUP) for the treatment of pain...
  28. pmc Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network
    Li Tzy Wu
    Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University Medical Center, Box 3419, Durham, NC 27710, USA
    J Psychiatr Res 46:360-9. 2012
    ..To address an urgent need for screening of substance use problems in medical settings, we examined substance-specific dependence criteria as potential brief screeners for the detection of patients with a substance use disorder (SUD)...
  29. pmc Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience
    Leslie Amass
    Friends Research Institute, Inc, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    Am J Addict 13:S42-66. 2004
    ....
  30. ncbi request reprint Methamphetamine abstinence syndrome: preliminary findings
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
    Am J Addict 13:248-55. 2004
    ..The abstinence syndrome associated with methamphetamine dependence varied considerably in intensity and duration but generally was mild and resolved quickly for most individuals...
  31. ncbi request reprint Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use
    Steven Shoptaw
    UCLA Integrated Substance Abuse Program, Los Angeles, Calif 90025, USA
    J Clin Psychiatry 64:1440-8. 2003
    ..This screening trial evaluated whether the GABAB agonist baclofen demonstrated sufficient clinical efficacy to recommend an adequately powered trial of the medication as a pharmacotherapy for cocaine dependence...
  32. ncbi request reprint Diffusion of substance abuse treatment: will buprenorphine be a success?
    Walter Ling
    UCLA Integrated Substance Abuse Programs, Neuropsychiatric Institute and Hospital, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Psychoactive Drugs . 2004
    ..Clinician attitude and the extent to which they embrace buprenorphine will play an important role in determining the future success of this medication...
  33. pmc Predictors of outcome after short-term stabilization with buprenorphine
    Maureen Hillhouse
    Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90025, USA
    J Subst Abuse Treat 44:336-42. 2013
    ..Criminal activity and opioid use in the last 30 days were significantly associated with shorter treatment stays. The benefits of identifying individual characteristics that may predict treatment response are discussed...
  34. pmc Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy
    Peggy Compton
    School of Nursing, University of California, Los Angeles, CA 90095 6918, USA
    J Pain 13:401-9. 2012
    ..The effects of nonpharmacologic therapy and previous heroin use may explain increased hyperalgesia found with treatment...
  35. ncbi request reprint Structural abnormalities in the brains of human subjects who use methamphetamine
    Paul M Thompson
    Laboratory of Neuroimaging, Brain Mapping Division, Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1769, USA
    J Neurosci 24:6028-36. 2004
    ..These brain substrates may help account for the symptoms of MA abuse, providing therapeutic targets for drug-induced brain injury...
  36. pmc Comparing buprenorphine induction experience with heroin and prescription opioid users
    Suzanne Nielsen
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    J Subst Abuse Treat 43:285-90. 2012
    ..The findings of this study suggest that existing buprenorphine induction practices developed for heroin users appear to be equally effective with PO users...
  37. ncbi request reprint Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)
    Steven Shoptaw
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    Addiction 100:78-90. 2005
    ..5 mg per week (n = 15); and placebo three times daily (n = 15) as potential pharmacotherapies for cocaine dependence...
  38. ncbi request reprint Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting
    Matthew Torrington
    University of California, Los Angeles, USA
    J Addict Dis 26:93-9. 2007
    ..Physicians may benefit from this information by using it to tailor comprehensive treatment and medical care plans for opioid-dependent patients taking buprenorphine...
  39. ncbi request reprint The effect of relapse on cognition in abstinent methamphetamine abusers
    Sara L Simon
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA
    J Subst Abuse Treat 27:59-66. 2004
    ..Relapse to methamphetamine use may affect episodic memory differently than it affects the other cognitive functions measured...
  40. ncbi request reprint Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Boulevard, Los Angeles, CA 90024, USA
    Addict Behav 28:817-21. 2003
    ..If these findings are replicated in a larger sample, then it may be necessary to reconsider the applicability of the opponent process model to cocaine addiction in humans...
  41. ncbi request reprint Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine
    Peggy Compton
    School of Nursing, University of California at Los Angeles, Factor Building 4 246, Box 956918, Los Angeles, CA 90095 6918, USA
    Drug Alcohol Depend 82:25-31. 2006
    ....
  42. pmc Comparison of behavioral treatment conditions in buprenorphine maintenance
    Walter Ling
    Integrated Substance Abuse Programs, University of California, Los Angeles, CA, USA
    Addiction 108:1788-98. 2013
    ..This randomized controlled trial compared the effectiveness of four behavioral treatment conditions provided with buprenorphine and medical management (MM) for the treatment of opioid dependence...
  43. doi request reprint Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients
    Peggy A Compton
    Acute Care Section, School of Nursing, University of California at Los Angeles, Factor Building 4 246, Box 956918, Los Angeles, CA 90095 6918, USA
    Addict Biol 13:393-402. 2008
    ..These results support that chronic high-dose NMDA antagonism does not improve tolerance for pain in MM patients, although a gender effect on DEX response is suggested...
  44. doi request reprint Health conditions in methamphetamine-dependent adults 3 years after treatment
    Larissa J Mooney
    From the UCLA Integrated Substance Abuse Programs L J M, S G E, P M C, M H, J H, W L, R R, Los Angeles, CA University of California School of Medicine A A, Los Angeles, CA and University of Hawaii School of Medicine W H, P C, Honolulu, HI
    J Addict Med 3:155-63. 2009
    ....
  45. ncbi request reprint Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study
    Steve Shoptaw
    Friends Research Institute, Los Angeles, CA, USA
    Exp Clin Psychopharmacol 12:126-35. 2004
    ..No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence...
  46. ncbi request reprint Cognitive performance of current methamphetamine and cocaine abusers
    Sara L Simon
    UCLA Integrated Substance Abuse Programs ISAP, USA
    J Addict Dis 21:61-74. 2002
    ..When compared to their matched non-using control groups, both MA and COC abusers were impaired on cognitive measures, but the type and degree of impairments were somewhat different...
  47. ncbi request reprint A comparison of patterns of methamphetamine and cocaine use
    Sara L Simon
    Los Angeles Addiction Research Consortium, USA
    J Addict Dis 21:35-44. 2002
    ..The cocaine pattern of fewer days of use, evening use, and more frequent doses per day fits a picture of recreational use, whereas the all-day-most-days methamphetamine pattern does not...
  48. ncbi request reprint Naltrexone and dysphoria: fact or myth?
    Karen Miotto
    UCLA Department of Psychiatry and Biobehavioral Sciences, 90024, USA
    Am J Addict 11:151-60. 2002
    ..These studies did not reveal dysphoria to be a serious side effect produced by naltrexone treatment. Additional studies to evaluate long-term endocrine effects and antidepressant combination therapy are warranted...
  49. ncbi request reprint Status of methamphetamine users 2-5 years after outpatient treatment
    Richard A Rawson
    Matrix Institute on Addictions, Los Angeles, CA 90025, USA
    J Addict Dis 21:107-19. 2002
    ..In general, the follow up status of the sample was much improved as compared to before treatment. However, headaches and depression were reported at a similar rate at follow up as had been reported at treatment admission...
  50. ncbi request reprint Apathy predicts hedonic but not craving response to cocaine
    Thomas F Newton
    David Geffen School of Medicine at the University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 90024, USA
    Pharmacol Biochem Behav 82:236-40. 2005
    ..The data reveal that cocaine-induced craving is not ubiquitous, and may not play a critical role in the maintenance of cocaine dependence. Overall, the findings suggest that apathy predicts hedonic but not craving response to cocaine...
  51. ncbi request reprint A screening trial of amantadine as a medication for cocaine dependence
    Steve Shoptaw
    Friends Research Institute, Inc, 11075 Santa Monica Blvd, Suite 350, Los Angeles, CA 90025, USA
    Drug Alcohol Depend 66:217-24. 2002
    ..There were no significant differences in frequency or severity of reported adverse events by treatment condition. These results provide moderate support for further study of amantadine for the treatment of cocaine dependence...
  52. doi request reprint Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial
    Yih Ing Hser
    University of California, Los Angeles, CA, USA
    Addiction 109:79-87. 2014
    ..To examine patient and medication characteristics associated with retention and continued illicit opioid use in methadone (MET) versus buprenorphine/naloxone (BUP) treatment for opioid dependence...
  53. doi request reprint Prescription opioid abuse, pain and addiction: clinical issues and implications
    Walter Ling
    UCLA Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90025 7539, USA
    Drug Alcohol Rev 30:300-5. 2011
    ..Given competing pressures faced by physicians to both diagnose and treat pain syndromes and identify individuals at risk for addictive disorders, the use of opioids in the treatment of pain poses a significant clinical challenge...
  54. ncbi request reprint Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing
    Peggy Compton
    From the UCLA School of Nursing PC, Los Angeles, CA UCLA Integrated Substance Abuse Programs WL, DL, CC, Los Angeles, CA Division of Pharmacotherapies and Medical Consequences of Drug Abuse CNC, National Institute on Drug Abuse, Bethesda, MD Center for Human Toxicology DEM, University of Utah, Salt Lake City, UT and University of Washington AH, Drug and Alcohol Institute, Seattle, WA
    J Addict Med 1:88-95. 2007
    ..At double the dose of tablet, there is no difference in steady state plasma concentrations. The bioavailability seems equivalent for the 2 formulations across all the dose levels...
  55. ncbi request reprint Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers
    Edythe D London
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, 760 Westwood Plaza, PO Box 175919, Los Angeles, CA 90024 1759, USA
    Arch Gen Psychiatry 61:73-84. 2004
    ..Mood disturbances in methamphetamine (MA) abusers likely influence drug use, but the neurobiological bases for these problems are poorly understood...
  56. ncbi request reprint Effect of oral ketorolac and gender on human cold pressor pain tolerance
    Peggy Compton
    School of Nursing, University of California at Los Angeles, Los Angeles, California, USA
    Clin Exp Pharmacol Physiol 30:759-63. 2003
    ....
  57. ncbi request reprint A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence
    Richard A Rawson
    University of California, Los Angeles, Integrated Substance Abuse Programs, 11075 Santa Monica Blvd, Suite 200, Los Angeles, CA 90025, USA
    Arch Gen Psychiatry 59:817-24. 2002
    ..This study compared 2 psychosocial approaches for the treatment of cocaine dependence: contingency management (CM) and cognitive-behavioral therapy (CBT)...
  58. ncbi request reprint Smoking cessation in methadone maintenance
    Steve Shoptaw
    Friends Research Institute, Los Angeles, CA, UCLA, Department of Psychiatry, Los Angeles, CA 90025, USA
    Addiction 97:1317-28; discussion 1325. 2002
    ..To evaluate relapse prevention (relapse prevention) and contingency management (contingency management) for optimizing smoking cessation outcomes using nicotine replacement therapy for methadone-maintained tobacco smokers...
  59. ncbi request reprint Dancing with strangers: will U.S. substance abuse practice and research organizations build mutually productive relationships?
    Richard A Rawson
    UCLA Integrated Substance Abuse Programs ISAP, 11075 Santa Monica Boulevard, No 200, Los Angeles, CA 90025, USA
    Addict Behav 27:941-9. 2002
    ..However, while the music has started and the partners seem willing, there are still many obstacles to a successful dance...
  60. pmc Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network
    Li Tzy Wu
    Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University Medical Center, Box 3419, Durham, NC 27710, USA
    Drug Alcohol Depend 118:186-93. 2011
    ....
  61. ncbi request reprint Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
    Clin Neurophysiol 114:410-5. 2003
    ....
  62. ncbi request reprint Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine
    Olga V Lopatko
    Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, SA, Australia
    Drug Alcohol Depend 69:317-22. 2003
    ....
  63. ncbi request reprint Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone
    Paul J Fudala
    Veterans Affairs VA Medical Center, University of Pennsylvania School of Medicine, Philadelphia, USA
    N Engl J Med 349:949-58. 2003
    ..Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied...
  64. ncbi request reprint Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology
    Tiffanie Sim
    Los Angeles Addiction Research Consortium, USA
    J Addict Dis 21:75-89. 2002
    ..The preliminary data suggests that executive function deficits and some of the symptoms associated with long-term MA use may be due to the fact that a large proportion of MA addicts had ADHD symptomatology as children...
  65. ncbi request reprint If a US drug abuse epidemic fails to include a major east coast city, can it be called an epidemic?
    Richard A Rawson
    J Addict Dis 21:1-4. 2002
  66. ncbi request reprint Opiate recidivism in a drug-treatment program: comparison of hair and urine data
    Bradley K Charles
    Center for Human Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Anal Toxicol 27:412-28. 2003
    ..Urine appeared to be a more sensitive indicator of changes in the pattern(s) of drug use during the course of clinical drug treatment...
  67. ncbi request reprint Will the methamphetamine problem go away?
    Richard A Rawson
    UCLA Integrated Substance Abuse Programs, UCLA Department of Psychiatry, USA
    J Addict Dis 21:5-19. 2002
    ..This article reviews the issues concerning the future of the methamphetamine problem in the US and provides some recommendations for setting priorities to address the problem...
  68. ncbi request reprint A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence
    Bankole A Johnson
    Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA 22908 0623, USA
    Int J Neuropsychopharmacol 11:1-14. 2008
    ..These findings should be viewed in light of the possibility that a less intensive cognitive behavioural therapy regimen might have yielded more positive results in this initial phase II trial exploring for the efficacy of ondansetron...
  69. ncbi request reprint Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations
    Peter Athanasos
    Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, SA 5005, Australia
    Pain 120:267-75. 2006
    ..While even higher morphine doses may achieve some pain relief, this may be at the cost of unacceptable respiratory depression...
  70. doi request reprint Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST)
    Rachel Humeniuk
    Drug and Alcohol, Services Council, Adelaide, Australia
    Addiction 103:1039-47. 2008
    ..The concurrent, construct and discriminative validity of the World Health Organization's Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) were examined in a multi-site international study...
  71. ncbi request reprint Medications development: successes and challenges
    Frank Vocci
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, USA
    Pharmacol Ther 108:94-108. 2005
    ..Initial studies are underway. Both agonist and antagonist approaches will be evaluated. Additionally, medications will be tested in cannabis-dependent patients for the management of insomnia, withdrawal, and concurrent depression...
  72. ncbi request reprint Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition
    Sandy Venneman
    Medication Development Unit, Research Service, and Psychiatry Service, West Los Angeles VA Medical Center, California, USA
    J Neuropsychiatry Clin Neurosci 18:208-16. 2006
    ..Failure to complete the trial was not explained by depression, craving, benzoylecgonine levels or quantitative electroencephalogram (QEEG) power; thus cordance may help identify attrition risk...
  73. ncbi request reprint Bupropion for the treatment of methamphetamine dependence
    Ahmed M Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
    Neuropsychopharmacology 33:1162-70. 2008
    ....
  74. ncbi request reprint The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity
    Ahmed Elkashef
    Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Addiction 102:107-13. 2007
    ..This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously...
  75. ncbi request reprint Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region
    Michael Farrell
    National Addiction Centre, 4 Windsor Walk, London SE5 8AF, UK
    Addiction 97:771-2. 2002
  76. ncbi request reprint Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects
    Arne Astrup
    Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, 30 Rolighedsvej, 1958 Frederiksberg C, Denmark
    Obesity (Silver Spring) 15:1717-31. 2007
    ..To evaluate the efficacy and safety of the selective dopamine D1/D5 antagonist ecopipam for the treatment of obesity...
  77. ncbi request reprint Use of methamphetamine by young people: is there reason for concern?
    Richard A Rawson
    Addiction 102:1021-2. 2007
  78. ncbi request reprint Cochrane systematic reviews: time for an introduction and appraisal
    Walter Ling
    Drug Alcohol Depend 73:217-8. 2004
  79. ncbi request reprint The Clinical Opiate Withdrawal Scale (COWS)
    Donald R Wesson
    CNS Medications Development, Oakland, California, USA
    J Psychoactive Drugs 35:253-9. 2003
    ..PDF formatted versions of the COWS are also available from the websites of the American Society of Addiction Medicine, the California Society of Addiction Medicine, the UCLA Integrated Substance Abuse Programs, and AlcoholMD.com...
  80. ncbi request reprint Substance use and treatment options in Cambodia
    Rachel Humeniuk
    WHO Collaborating Centre, Parkside, South Australia
    Drug Alcohol Rev 23:365-7. 2004
  81. ncbi request reprint Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence
    Dennis W Raisch
    Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA
    J Am Pharm Assoc (2003) 45:23-32. 2005
    ..To assess the perceptions and attitudes of pharmacists and pharmacy technicians involved in an office-based opioid dependence treatment program using buprenorphine/naloxone...
  82. doi request reprint World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism
    Michael Soyka
    Psychiatric Hospital Meiringen, Meiringen, Switzerland
    World J Biol Psychiatry 9:6-23. 2008
    ..This first part of the guidelines covers the treatment of alcohol dependence; Part 2 will be devoted to the treatment of drug dependence...